155 related articles for article (PubMed ID: 37185612)
41. High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis.
Xu Y; Ogose A; Kawashima H; Hotta T; Ariizumi T; Li G; Umezu H; Endo N
Oncol Rep; 2011 Mar; 25(3):599-607. PubMed ID: 21234520
[TBL] [Abstract][Full Text] [Related]
42. MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma.
Kaya M; Wada T; Nagoya S; Sasaki M; Matsumura T; Yamaguchi T; Hasegawa T; Yamashita T
Skeletal Radiol; 2008 Dec; 37(12):1085-90. PubMed ID: 18629459
[TBL] [Abstract][Full Text] [Related]
43. Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma.
Yamashita A; Suehara Y; Hayashi T; Takagi T; Kubota D; Sasa K; Hasegawa N; Ishijima M; Yao T; Saito T
Virchows Arch; 2022 Oct; 481(4):1-17. PubMed ID: 35705750
[TBL] [Abstract][Full Text] [Related]
44. Myxoid malignant fibrous histiocytoma presenting as a midline nasal mass.
DeRosa J; Smit JR
Ear Nose Throat J; 2012 Apr; 91(4):E3-5. PubMed ID: 22522364
[TBL] [Abstract][Full Text] [Related]
45. Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma.
Sun H; Liu J; Hu F; Xu M; Leng A; Jiang F; Chen K
Front Genet; 2023; 14():1109491. PubMed ID: 36873946
[TBL] [Abstract][Full Text] [Related]
46. Preoperative Evaluation of Myxofibrosarcoma: Prognostic Value and Reproducibility of Different Features on MRI.
MÜhlhofer H; Gersing A; Pfeiffer D; WÖrtler K; Lenze U; Lenze F; Lallinger V; Haller B; Burgkart R; VON Eisenhart-Rothe R; Knebel C
Anticancer Res; 2020 Oct; 40(10):5793-5800. PubMed ID: 32988907
[TBL] [Abstract][Full Text] [Related]
47. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases.
Vodanovich DA; Spelman T; May D; Slavin J; Choong PFM
ANZ J Surg; 2019 Sep; 89(9):1045-1050. PubMed ID: 31364245
[TBL] [Abstract][Full Text] [Related]
48. Usefulness of argyrophilic nucleolar organizer staining for predicting prognosis of patients with recurrent soft tissue sarcoma.
Kuratsu S; Ohsawa M; Naka N; Myoui A; Tomita Y; Uchida A; Ono K; Aozasa K
Oncology; 1994; 51(3):244-50. PubMed ID: 8196907
[TBL] [Abstract][Full Text] [Related]
49. Oncologic outcomes in myxofibrosarcomas: the role of a multidisciplinary approach and surgical resection margins.
Rhee I; Spazzoli B; Stevens J; Hansa A; Spelman T; Pang G; Guiney M; Powell G; Choong P; Di Bella C
ANZ J Surg; 2023 Mar; 93(3):577-584. PubMed ID: 36772961
[TBL] [Abstract][Full Text] [Related]
50. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
[TBL] [Abstract][Full Text] [Related]
51. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific?
Choong PF; Akerman M; Willén H; Andersson C; Gustafson P; Alvegård T; Rydholm A
APMIS; 1995 Nov; 103(11):797-805. PubMed ID: 8546844
[TBL] [Abstract][Full Text] [Related]
52. Intramuscular high-grade myxofibrosarcoma of left buttock of 66-year-old male patient - approach to systematic histopathological reporting.
Wincewicz A; Lewitowicz P; Matykiewicz J; Głuszek S; Sulkowski S
Rom J Morphol Embryol; 2015; 56(4):1523-8. PubMed ID: 26743304
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Factors and Outcomes for Patients With Myxofibrosarcoma: A 13-Year Retrospective Evaluation.
Mühlhofer HML; Lenze U; Gersing A; Lallinger V; Burgkart R; Obermeier A; VON Eisenhart-Rothe R; Knebel C
Anticancer Res; 2019 Jun; 39(6):2985-2992. PubMed ID: 31177139
[TBL] [Abstract][Full Text] [Related]
54. Primary cutaneous myxofibrosarcoma mimicking pleomorphic hyalinizing angiectatic tumor (PHAT): a potential diagnostic pitfall.
Mitsuhashi T; Barr RJ; Machtinger LA; Cassarino DS
Am J Dermatopathol; 2005 Aug; 27(4):322-6. PubMed ID: 16121054
[TBL] [Abstract][Full Text] [Related]
55. Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
Lee AY; Agaram NP; Qin LX; Kuk D; Curtin C; Brennan MF; Singer S
Ann Surg Oncol; 2016 Mar; 23(3):818-25. PubMed ID: 26759307
[TBL] [Abstract][Full Text] [Related]
56. Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?
Lucarelli E; De Vita A; Bellotti C; Frisoni T; Vanni S; Guerrieri AN; Pannella M; Mercatali L; Gambarotti M; Duchi S; Miserocchi G; Maioli M; Liverani C; Ibrahim T
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958307
[TBL] [Abstract][Full Text] [Related]
57. Soft tissue sarcoma of the hand.
Campanacci M; Bertoni F; Laus M
Ital J Orthop Traumatol; 1981 Dec; 7(3):313-27. PubMed ID: 6290421
[TBL] [Abstract][Full Text] [Related]
58. Low-grade myxofibrosarcoma presenting at the site of prior high-grade disease.
Bandino JP; Norton SA; Aldrich SL; Wisco OJ; Hodson DS; Murchland MR; Grande DJ
J Cutan Pathol; 2011 Oct; 38(10):808-13. PubMed ID: 21752050
[TBL] [Abstract][Full Text] [Related]
59. Myxoid malignant fibrous histiocytoma mimicking papular mucinosis.
Stephen MR; Morton R
Am J Dermatopathol; 1998 Jun; 20(3):290-5. PubMed ID: 9650705
[TBL] [Abstract][Full Text] [Related]
60. What is an adequate margin for infiltrative soft-tissue sarcomas?
Fujiwara T; Stevenson J; Parry M; Tsuda Y; Tsoi K; Jeys L
Eur J Surg Oncol; 2020 Feb; 46(2):277-281. PubMed ID: 31627932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
